Tudor Investment Corp ET AL Buys New Position in ANI Pharmaceuticals, Inc. $ANIP

Tudor Investment Corp ET AL purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, Holdings Channel reports. The institutional investor purchased 11,850 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,085,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Divisadero Street Capital Management LP acquired a new position in shares of ANI Pharmaceuticals during the third quarter worth $21,454,000. Assenagon Asset Management S.A. grew its holdings in ANI Pharmaceuticals by 259.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 46,328 shares of the specialty pharmaceutical company’s stock valued at $4,244,000 after purchasing an additional 33,438 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $1,597,000. Decker Retirement Planning Inc. increased its stake in ANI Pharmaceuticals by 76,862.5% during the 3rd quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after buying an additional 36,894 shares during the period. Finally, Apis Capital Advisors LLC increased its stake in ANI Pharmaceuticals by 28.1% during the 3rd quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after buying an additional 36,000 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Ori Gutwerg sold 2,060 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total transaction of $157,590.00. Following the transaction, the senior vice president owned 84,782 shares of the company’s stock, valued at approximately $6,485,823. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares of the company’s stock, valued at $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 27,860 shares of company stock worth $2,114,771. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Trading Up 1.2%

NASDAQ ANIP opened at $73.71 on Tuesday. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of 21.94 and a beta of 0.52. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50. The company’s fifty day moving average price is $77.37 and its two-hundred day moving average price is $83.58.

Analysts Set New Price Targets

A number of research firms have weighed in on ANIP. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Guggenheim lifted their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.